0000000000661933

AUTHOR

Elisabeth Bacon

showing 2 related works from this author

Medications between psychiatric and addictive disorders

2016

International audience; Introduction : Many epidemiological studies have revealed a frequent co-occurrence of psychiatric and substance use disorders. The term used in the literature to refer to this co-occurrence is dual diagnosis. The high prevalence of dual diagnosis has led physicians to observe the effects of medication prescribed to treat psychiatric disorders on the co-occurring substance use disorder and vice versa. The concept of medications between psychiatric and addictive disorders stems from these clinical observations, alongside which, however, it has developed from the observation that both psychiatric and substance use disorders share common neurobiological pathways and trig…

medicine.medical_specialtyPsychotherapistSubstance-Related Disordersmedia_common.quotation_subject[SDV]Life Sciences [q-bio][ SDV.MHEP.PSM ] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthAddictionModafinilMirtazapine[ SCCO.PSYC ] Cognitive science/Psychology03 medical and health sciences0302 clinical medicineCognitionEpidemiology of child psychiatric disordersmedicineAnimalsHumansDual diagnosisMedical prescriptionPsychiatryClozapineBiological PsychiatryDepression (differential diagnoses)ComputingMilieux_MISCELLANEOUSmedia_commonPharmacologyPsychotropic DrugsDepressionAddictionmedicine.disease3. Good health030227 psychiatrySubstance abuseClinical researchSchizophreniaDiagnosis Dual (Psychiatry)[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health[SCCO.PSYC]Cognitive science/PsychologySchizophreniaDual diagnosisPsychologyPsychiatric disorders030217 neurology & neurosurgery
researchProduct

Cognitive effects of labeled addictolytic medications

2017

Abstract Introduction Alcohol, tobacco, and illegal drug usage is pervasive throughout the world, and abuse of these substances is a major contributor to the global disease burden. Many pharmacotherapies have been developed over the last 50 years to target addictive disorders. While the efficacy of these pharmacotherapies is largely recognized, their cognitive impact is less known. However, all substance abuse disorders are known to promote cognitive disorders like executive dysfunction and memory impairment. These impairments are critical for the maintenance of addictive behaviors and impede cognitive behavioral therapies that are regularly administered in association with pharmacotherapie…

medicine.medical_specialtySubstance-Related Disordersmedia_common.quotation_subjectAlcohol abuse03 medical and health scienceschemistry.chemical_compoundCognition0302 clinical medicinemedicineAnimalsHumansVareniclinePsychiatryBiological PsychiatryNalmefenemedia_commonPharmacologyAddictionCognitionmedicine.disease030227 psychiatrySubstance abusechemistryPsychology030217 neurology & neurosurgeryCentral Nervous System AgentsClinical psychologymedicine.drugExecutive dysfunctionBuprenorphineProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct